About Soneas
Soneas is a company based in Budapest (Hungary) founded in 1996 was acquired by Uquifa in May 2018. Soneas offers products and services including Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing. Soneas operates in a competitive market with competitors including Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
- Headquarter Budapest, Hungary
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Soneas Chemicals Ltd
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Uquifa
(May 16, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Soneas
Soneas offers a comprehensive portfolio of products and services, including Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing.
Early phase development for chemical projects and trials.
Supports chemistry understanding and innovation processes.
cGMP production of APIs and intermediates for trials.
ISO-certified large-scale chemical manufacturing operations.
Funding Insights of Soneas
Detailed funding history for Soneas
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Soneas
Soneas has secured backing from 1 investor. Prominent investors backing the company include UQUIFA Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CDMO company manufacturing APIs and intermediates
|
Locked | Locked | Locked |
Investor details for Soneas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Soneas
Investment portfolio details for Soneas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Soneas
Detailed financials for Soneas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Soneas Comparisons
Peer comparison for Soneas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Soneas
Soneas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Laurus Labs, Sterling Pharma Solutions, Provepharm Life Solutions, Symbiotec and Jubilant Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical and biotechnology company
|
|
| Locked | Locked | Locked |
Contract development, manufacturing, and analytical services for APIs are offered.
|
|
| Locked | Locked | Locked |
APIs and drug products are developed and valorized in pharmaceuticals.
|
|
| Locked | Locked | Locked |
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
|
|
| Locked | Locked | Locked |
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
|
|
| Locked | Locked | Locked |
APIs are manufactured and custom synthesis services are provided.
|
Detailed competitors of Soneas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Soneas
Complete news archive for Soneas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Soneas
Soneas was founded in 1996.
Soneas is headquartered in Budapest, Hungary.
Soneas (formerly known as Ubichem Pharma Group) is a CDMO offering its services for API and intermediate development. The company uses catalytic olefine metathesis, in addition to other traditional manufacturing methods. The companys service portfolio includes process development (including Route selection and safety evaluation, Availability and cost of key raw materials, Process optimisation and scale-up, and Isolation and purification), cGMP API manufacture (Preclinical to commercial supply through kilo labs and pilot plants), Intermediate custom synthesis and manufacture, and analytical support services (Analytical MD MV,Impurities reference standards, Salt screening crystallisation studies, Stability studies). Soneas has a strategic partnership with XiMO AG, a Swiss-based company focused on the development and application of proprietary metathesis catalysts and founded by Richard R. Schrock, the co-winner of 2005 Nobel prize. Metathesis catalysts made up of Molybdenum and Tungsten are cheaper than those made up of Ruthenium and also help in reducing the catalytic load.
Soneas's top competitors include Laurus Labs, Symbiotec and Sterling Pharma Solutions.
Soneas offers Discovery Process, R&D Services, GMP Manufacturing, and Large Scale Manufacturing.
Soneas has 1 investor. Key investors include UQUIFA Group.